119-HRES-775 Investigative Journalist Impact Analysis

Summary

- What the measure does: H.Res. 775 expresses the House’s support for designating September 2025 as National Ovarian Cancer Awareness Month; simple resolutions state the sense of one chamber and do not have the force of law. [1]Congress.gov — “Sense of” Resolutions and Provisions (CRS Report)

- Baseline burden: In 2025, U.S. ovarian cancer burden is on the order of 20,000 new cases and 12,000 deaths; 5‑year relative survival across all stages is about 51%, exceeding 90% when localized. [5]American Cancer Society — ACS press release: American Cancer Society and Break…[6]American Cancer Society — Survival Rates for Ovarian Cancer

- Evidence constraints: There is no recommended routine screening for average‑risk, asymptomatic women; large randomized trials (PLCO, UKCTOCS) showed no mortality reduction, and screening can cause harms from false positives and unnecessary surgery. [2]USPSTF — Final Recommendation Statement: Ovarian Cancer: Screening[7]JAMA — Effect of Screening on Ovarian Cancer Mortality (PLCO Trial)[8]MRC Clinical Trials Unit at UCL — UKCTOCS: Screening for ovarian cancer did not…

Economic Effects

Direct federal outlays are not authorized by this resolution. Effects, if any, arise indirectly through public and private actions during an awareness month.

• Federal budget: Simple resolutions do not appropriate funds; any federal communications would occur within existing agency budgets. [1]Congress.gov — “Sense of” Resolutions and Provisions (CRS Report)
• Research and public‑health ecosystem: NCI’s FY2025 budget remains roughly flat at about $7.22B; CDC’s ovarian cancer activities have historically been funded at modest levels (about $15M in FY2024), implying limited capacity for sudden federal program expansion absent new appropriations. [9]National Cancer Institute — NCI Budget and Appropriations (FY2025)[10]AACR — AACR Cancer Policy Monitor (Apr 9, 2024): Federal cancer program funding…
• Healthcare utilization: Awareness months reliably increase public information‑seeking (including for ovarian cancer), which can transiently raise clinic contacts and diagnostic evaluations; net costs depend on whether visits lead to indicated risk assessment/genetic counseling versus low‑value testing. [3]ecancermedicalscience (PMC) — The impact of monthly campaigns and media coverag…
• Low‑value care risk: Public messaging that prompts CA‑125 or ultrasound screening in average‑risk, asymptomatic women could increase false positives, surgical workups, and complication costs without mortality benefit (as shown in PLCO). [2]USPSTF — Final Recommendation Statement: Ovarian Cancer: Screening[7]JAMA — Effect of Screening on Ovarian Cancer Mortality (PLCO Trial)
• Philanthropy and local commerce: September events (runs/walks, teal‑lighting, campaigns) can spur charitable giving and small local spending; impacts are diffuse and not systematically quantified. [11]Web search · turn 10 #0[12]Web search · turn 10 #5

Social Effects

Primary impacts are informational: who hears what, and what they do with it.

• Public awareness: Awareness months measurably lift search interest for ovarian cancer in September, creating opportunities to disseminate symptom lists, family‑history prompts, and care‑navigation resources. [3]ecancermedicalscience (PMC) — The impact of monthly campaigns and media coverag…
• Clinical conversations: Evidence‑based messaging can steer average‑risk women away from screening and toward risk‑appropriate actions (e.g., documenting family history; discussing persistent symptoms). [2]USPSTF — Final Recommendation Statement: Ovarian Cancer: Screening
• Patients already diagnosed: Guidelines recommend offering all individuals with epithelial ovarian cancer germline testing (and, if negative, tumor testing) to guide therapy and cascade testing; awareness could improve adherence. [4]ASCO / Journal of Clinical Oncology (PMC) — ASCO Guideline: Germline and Somati…
• Equity: Black and some Native American patients are less likely to have elevated CA‑125 at diagnosis and face worse outcomes; messaging that over‑relies on CA‑125 may inadvertently widen disparities unless paired with tailored guidance. [13]JAMA Network Open — CA‑125 Levels at Diagnosis by Race and Ethnicity (JAMA Netw…[14]Obstetrics & Gynecology (PMC) — Health Disparities in Ovarian Cancer: Evidence…
• Underuse of genetics: Despite longstanding recommendations, only about one‑third of U.S. ovarian cancer patients had germline testing in 2013–2014; targeted campaigns could help close this gap. [15]Journal of Clinical Oncology — Genetic Testing and Results in a Population‑Base…
• Professional practice: Clinician‑facing content can highlight risk‑reducing options (e.g., opportunistic salpingectomy during benign pelvic surgery) and referral to gynecologic oncologists, both linked to improved outcomes. [16]ACOG — ACOG Committee Opinion No. 774: Opportunistic Salpingectomy

Environmental Effects

- Direct environmental impact is negligible: the resolution itself changes no land use, energy, or emissions policy. Any marginal footprint would stem from awareness events (travel, materials), which is small and temporary relative to federal programs. (No citation required.)

Temporal Analysis

• Immediate (Sept–Dec 2025): Spikes in search interest and media coverage; local proclamations and fundraising; possible short‑term uptick in clinic contacts for symptom evaluation and genetic‑risk inquiries. [3]ecancermedicalscience (PMC) — The impact of monthly campaigns and media coverag…
• 1–3 years: If messaging aligns to evidence, potential gains include higher rates of universal genetic testing among those diagnosed, better referral patterns to gynecologic oncologists, and increased uptake of risk‑reducing salpingectomy when clinically appropriate. [4]ASCO / Journal of Clinical Oncology (PMC) — ASCO Guideline: Germline and Somati…[16]ACOG — ACOG Committee Opinion No. 774: Opportunistic Salpingectomy
• Longer term: No expectation of population‑level mortality change from screening in average‑risk women unless novel, validated tests emerge; National Academies emphasize persistent knowledge gaps necessitating research investment. [8]MRC Clinical Trials Unit at UCL — UKCTOCS: Screening for ovarian cancer did not…[17]National Academies Press — Ovarian Cancers: Evolving Paradigms in Research and…

Unintended Consequences

Risks if messaging deviates from evidence or overlooks structural gaps.

Assessment

Overall stance (analytical, not advocacy): Neutral. H.Res. 775 has negligible direct economic or environmental impact and plausible social upside if it channels attention toward high‑value actions (documenting family history; symptom vigilance; universal genetic testing for those diagnosed; evidence‑based prevention like opportunistic salpingectomy). The downside risk is misinterpreting awareness as endorsement of population screening—contrary to USPSTF and trial evidence—and inadvertently worsening disparities via one‑size‑fits‑all testing messages. [2]USPSTF — Final Recommendation Statement: Ovarian Cancer: Screening[7]JAMA — Effect of Screening on Ovarian Cancer Mortality (PLCO Trial)[16]ACOG — ACOG Committee Opinion No. 774: Opportunistic Salpingectomy[13]JAMA Network Open — CA‑125 Levels at Diagnosis by Race and Ethnicity (JAMA Netw…

Sourcing

Key datasets and guidance cited throughout this analysis.

• American Cancer Society (incidence, survival, 2025 updates). [6]American Cancer Society — Survival Rates for Ovarian Cancer[5]American Cancer Society — ACS press release: American Cancer Society and Break…
• CDC U.S. Cancer Statistics and ovarian cancer overview. [18]CDC — Ovarian Cancer Statistics
• USPSTF Final Recommendation: Ovarian cancer screening (no routine screening). [2]USPSTF — Final Recommendation Statement: Ovarian Cancer: Screening
• Randomized trials: PLCO (JAMA 2011) and UKCTOCS (Lancet 2021 summaries). [7]JAMA — Effect of Screening on Ovarian Cancer Mortality (PLCO Trial)[8]MRC Clinical Trials Unit at UCL — UKCTOCS: Screening for ovarian cancer did not…
• Genetic testing guidelines (ASCO) and practice statements (SGO). [4]ASCO / Journal of Clinical Oncology (PMC) — ASCO Guideline: Germline and Somati…[19]Society of Gynecologic Oncology — SGO Clinical Practice Statement (2024): Germl…
• Disparities reviews and biomarker sensitivity by race (JAMA Network Open 2025). [14]Obstetrics & Gynecology (PMC) — Health Disparities in Ovarian Cancer: Evidence…[13]JAMA Network Open — CA‑125 Levels at Diagnosis by Race and Ethnicity (JAMA Netw…
• Risk‑reducing surgery (ACOG Committee Opinion No. 774). [16]ACOG — ACOG Committee Opinion No. 774: Opportunistic Salpingectomy
• Awareness‑month impact on public interest (Google Trends analyses). [3]ecancermedicalscience (PMC) — The impact of monthly campaigns and media coverag…
• Budget context (NCI; CDC ovarian program). [9]National Cancer Institute — NCI Budget and Appropriations (FY2025)[10]AACR — AACR Cancer Policy Monitor (Apr 9, 2024): Federal cancer program funding…

Key Metrics